Jury Awards Infosint $15M In Lexapro Patent Fight

By Evan Weinberger

Law360, New York (October 19, 2009, 5:32 PM ET) -- Lundbeck A/S and Forest Laboratories Inc. will have to pay Infosint SA a $15 million reasonable royalty award now that a federal jury has ruled that Infosint's patent for making the antidepressant citalopram is valid.

A jury in the U.S. District Court for the Southern District of New York on Thursday found that a process used by Lundbeck for making racemic citalopram and escitalopram, the active ingredients in the antidepressant, infringed Infosint's patented process for making 5-carboxyphthalide, a starting material for the synthesis of citalopram....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles